Stock ARMP ARMATA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Market Closed - Nyse
Other stock markets
 16:00:00 2024-05-03 EDT 		5-day change 1st Jan Change
2.49 USD 0.00% Intraday chart for Armata Pharmaceuticals, Inc. -9.78% -23.15%
03-21 Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M MT
03-21 Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ARMATA PHARMACEUTICALS, INC. Stock Armata Pharmaceuticals, Inc.
-23.15% 90.02M -
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.9B
B-
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.7B
B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. ARMP Stock
  4. Ratings Armata Pharmaceuticals, Inc.